Saquinavir Enfuvirtide

Enfuvirtide is not metabolized to a significant extent and is not known to alter the concentrations of any coadministered drugs. Ritonavir, rifampin, or ritonavir plus saquinavir did not alter enfuvirtide concentrations. 

Ritonavir caused a minor increase in enfuvirtide exposure, which is not clinically relevant. Saquinavir/ritonavir had little effect on enfuvirtide. 

Subcutaneous enfuvirtide 90 mg twice daily was given for 7 days to 24 HIV-positive subjects with either ritonavir 200 mg twice daily or saquinavir/ritonavir 1 g/100 mg twice daily given for the last 4 days. Ritonavir caused a minor 24% increase in the AUC of enfuvirtide, and saquinavir/ritonavir caused a 14% increase in the AUC of enfuvirtide. Such small increases in enfuvirtide exposure are not clinically relevant. No special precautions appear warranted during concurrent use. ... 

Ruxrungdiam K, Boyd M, Bellibas SE, Zhang X, Dorr A, Kolis S, Kinchelow T, Buss N, I tel IH. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. J Clin Pharmacol (2004) 44, W3-802. 

---

See also in sourсe #XX -- [ ]

---